Article Text

Download PDFPDF

P9 Increase of IL10 and INFA2 are associated to clinical activity in systemic lupus erythematous patients
  1. Elena Grau García1,2,
  2. Iago Alcántara Álvarez2,
  3. Inmaculada Chalmeta Verdejo2,
  4. Hikmat Charia1,2,
  5. Marta de la Rubia Navarro2,
  6. Luis González Puig2,
  7. Anderson Víctor Huaylla Quispe2,
  8. José Ivorra Cortés2,
  9. Samuel Leal1,2,
  10. Isabel Martínez Cordellat2,
  11. Laura Mas Sánchez2,
  12. Pablo Francisco Muñoz Martínez2,
  13. Rosa Negueroles Albuixech2,
  14. José Eloy Oller Rodríguez2,
  15. Daniel Ramos Castro2,
  16. Carmen Riesco Bárcena2,
  17. Alba Torrat Novés2,
  18. Ernesto Tovar Sugrañes2,
  19. Elvira Vicens Bernabeu2,
  20. Belén Villanueva Mañes2,
  21. Inés Cánovas Olmos2,
  22. Carmen Nájera Herranz2,
  23. Guillen Sada Urmeneta3 and
  24. José Andrés Román Ivorra2
  1. 1Rheumatology Research Group,,Instituto de Investigación Sanitaria La Fe, HUP La Fe, Valencia, Spain
  2. 2Rheumatology Department, HUP La Fe, Valencia, Spain
  3. 3Rheumatology Section, Reina Sofía Hospital, Navarra, Spain

Abstract

Objective We aimed to analyze the association between inflammatory cytokine levels (IFN-a2, IFN-b, IFN-g, IL10 and BLyS) and disease activity for a 12 months of follow-up in SLE patients.

Methods A longitudinal, observational prospective study with evaluations at baseline and follow-up visits every 3 months in SLE patients (SLICC 2012 criteria) and 65 healthy controls was performed. In SLE patients complete laboratory test, clinical evaluation and SLEDAI score was carried out. We analyzed inflammatory cytokines serum levels by colorimetric methods in all cases.

Results 45 SLE patients (86.7% female) participated in the study, with a mean age at diagnosis of 32.8 (16.2) years and a mean time of disease evolution of 17.9 (11.4) years. The 28.9% of patients showed SLEDAI>6 at the basal visit. The 66.7% were under glucocorticoid treatment, 44.4% under immunosupressants (methotrexate, azatioprine, belimumab or mycophenolate) and 66.7% under antimalarials. SLEDAI and inflammatory cytokine levels during follow-up is shown in table 1.

Abstract P9 Table 1

Statistical analysis showed significant association between SLEDAI score and IL-10 (P=0.014) and IFNa2 (0.009), as well as a tendency with IFN-beta (P=0.057), independently of the time of follow-up. Regarding to clinical activity biomarkers, we observed an association between high levels of antidsDNA and elevated IFN-beta (P=0.005) and IFN-gamma (P=0.038), and low levels of C3 and an increment in IL-10 (P=0.006).

Patients under antimalarials treatment during follow-up exhibit low levels of IL-10 (P=0.012) and those under belimumab treatment showed high levels of BLyS (P<0.001). No influence of age at diagnosis, time of evolution, vitamin D levels, corticoids and tobacco use in cytokine levels was observed.

SLE patients were categorized by normal or high level of the five cytokines, based on the cytokine level above 2 SD of the mean in healthy controls. Despite the fact that no specific cytokine profile associated with clinical activity was observed, those patients with high SLEDAI score had increased levels of IL10.

Conclusion We observed an association between IL-10, IFN-alpha2, IFN-beta and IFN-gamma levels with clinical activity, independently of the time of follow-up. IL-10 levels may be influenced by antimalarial treatment and BLyS levels by belimumab treatment.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ .

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.